Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase EARLY_PHASE1 1Phase 1/2 1Phase 1 1

Status

Recruiting 2Completed 2Terminated 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Tumor-Agnostic 3Gastrointestinal 2Genitourinary 1

Conditions

Carcinoma, Basal Cell 15Neoplasms 5Pancreatic Neoplasms 4Stomach Neoplasms 3Ovarian Neoplasms 3Multiple Myeloma 3Medulloblastoma 3Colorectal Neoplasms 3Basal Cell Nevus Syndrome 3Urinary Bladder Neoplasms 2Lymphoma 2Hematologic Neoplasms 2Breast Neoplasms 2Brain Neoplasms 2Adenocarcinoma 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Platinum-Resistant Fallopian Tube Carcinoma 1Pancreatic Diseases 1Odontogenic Cysts 1Neuroectodermal Tumors, Primitive 1Neoplasms, Unknown Primary 1Neoplasms, Basal Cell 1Neoplasms by Site 1

Interventions

Gemcitabine 53Bevacizumab 52Cyclophosphamide 49Docetaxel 42Carboplatin 40pembrolizumab 37Paclitaxel 36Fluorouracil 36Cisplatin 35Radiotherapy 31Oxaliplatin 31Capecitabine 29Irinotecan 28Dexamethasone 27Leucovorin 25Cetuximab 25Nivolumab 24Doxorubicin 22Drug Therapy 21Erlotinib Hydrochloride 20Pemetrexed 19durvalumab 18trametinib 17fludarabine 16atezolizumab 16Trastuzumab 16Sunitinib 16Rituximab 16Prednisone 16Sorafenib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms × HhAntag691 × Clear all
NCT04341181 2025-07-25

ProTarget

Rigshospitalet, Denmark

Phase 2 Recruiting
300 enrolled
Tumor-Agnostic

Neoplasms

NCT02091141 2024-07-23

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Genentech, Inc.

Phase 2 Completed
673 enrolled 22 charts
GastrointestinalGenitourinary

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Neoplasms

NCT02925234 2024-01-24

DRUP

The Netherlands Cancer Institute

Phase 2 Recruiting
1,550 enrolled
Tumor-Agnostic

Neoplasms

NCT01088815 2019-04-26

Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
98 enrolled 14 charts
Gastrointestinal

Adenocarcinoma, Carcinoma, Digestive System Diseases, Digestive System Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Pancreatic Diseases, Pancreatic Neoplasms

NCT01096732 2014-01-08

HIPPoS

Cambridge University Hospitals NHS Foundation Trust

Phase 2 Terminated
3 enrolled
Tumor-Agnostic

Adenocarcinoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡